Headquartered in Alameda, CA Fiscal year ends December NYSE: PEN penumbrainc.com
Penumbra, Inc. is a medical device company focused on developing innovative technologies for challenging vascular conditions including ischemic stroke, venous thromboembolism (such as pulmonary embolism), and acute limb ischemia. The company's broad product portfolio centers on computer assisted vacuum thrombectomy (CAVT) and is designed to remove blood clots from head-to-toe with speed, safety, and simplicity. Penumbra operates two primary product categories: Thrombectomy, which is its core franchise, and Embolization and Access. The company supports healthcare providers, hospitals, and clinics in more than 100 countries. Penumbra is currently subject to a pending acquisition by Boston Scientific Corporation. Updated
Friday's top analyst upgrades and downgrades included Analog Devices, Boston Scientific, CrowdStrike, Enphase Energy, Frontier, International Paper, Nike, Petrobras, Truist Financial and VICI Properties.
Wednesday's top analyst upgrades and downgrades included Array Technology, Blink Charging, Carnival, Carrier Global, DocuSign, Fox, Marathon Petroleum, Occidental Petroleum, PagSeguro Digital, Paramount Global, Salesforce, Viking Therapeutics and Williams Companies.
Monday's top analyst upgrades and downgrades included Altice USA, Arista Networks, Block, Cardinal Health, ConocoPhillips, Datadog, GoodRx, Monster Beverage, PepsiCo, Spirit AeroSystems, Twilio and WeWork.
Penumbra, Inc. is a medical device company focused on developing innovative technologies for challenging vascular conditions including ischemic stroke, venous thromboembolism (such as pulmonary embolism), and acute limb ischemia.
24/7 Wall St.'s 12-month price target for PEN is $350.86, rated Buy. The Wall Street consensus target is $362.54. PEN price prediction →
